Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Maternal obesity influences expression and DNA methylation of the adiponectin and leptin systems in human third-trimester placenta.

Nogues P, Dos Santos E, Jammes H, Berveiller P, Arnould L, Vialard F, Dieudonné MN.

Clin Epigenetics. 2019 Feb 7;11(1):20. doi: 10.1186/s13148-019-0612-6.

2.

Recurrent Exposure of XEN Gel Stent Implant and Conjunctival Erosion.

Arnould L, Theillac V, Moran S, Gatinel D, Grise-Dulac A.

J Glaucoma. 2018 Nov 30. doi: 10.1097/IJG.0000000000001146. [Epub ahead of print]

PMID:
30676470
3.

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer.

Ledys F, Klopfenstein Q, Truntzer C, Arnould L, Vincent J, Bengrine L, Remark R, Boidot R, Ladoire S, Ghiringhelli F, Derangere V.

J Immunother Cancer. 2018 Nov 19;6(1):123. doi: 10.1186/s40425-018-0438-3.

4.

The EYE-MI Pilot Study: A Prospective Acute Coronary Syndrome Cohort Evaluated With Retinal Optical Coherence Tomography Angiography.

Arnould L, Guenancia C, Azemar A, Alan G, Pitois S, Bichat F, Zeller M, Gabrielle PH, Bron AM, Creuzot-Garcher C, Cottin Y.

Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4299-4306. doi: 10.1167/iovs.18-24090.

PMID:
30372758
5.

GREB1-CTNNB1 fusion transcript detected by RNA-sequencing in a uterine tumor resembling ovarian sex cord tumor (UTROSCT): A novel CTNNB1 rearrangement.

Croce S, Lesluyes T, Delespaul L, Bonhomme B, Pérot G, Velasco V, Mayeur L, Rebier F, Ben Rejeb H, Guyon F, McCluggage WG, Floquet A, Querleu D, Chakiba C, Devouassoux-Shisheboran M, Mery E, Arnould L, Averous G, Soubeyran I, Le Guellec S, Chibon F.

Genes Chromosomes Cancer. 2019 Mar;58(3):155-163. doi: 10.1002/gcc.22694. Epub 2019 Jan 7.

PMID:
30350331
6.

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.

Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F.

Br J Cancer. 2018 Oct;119(8):950-960. doi: 10.1038/s41416-018-0220-9. Epub 2018 Oct 15.

PMID:
30318514
7.

Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients.

Richard C, Fumet JD, Chevrier S, Derangère V, Ledys F, Lagrange A, Favier L, Coudert B, Arnould L, Truntzer C, Boidot R, Ghiringhelli F.

Clin Cancer Res. 2019 Feb 1;25(3):957-966. doi: 10.1158/1078-0432.CCR-18-1940. Epub 2018 Aug 28.

PMID:
30154227
8.

Tumor-derived granzyme B-expressing neutrophils acquire antitumor potential after lipid A treatment.

Martin A, Seignez C, Racoeur C, Isambert N, Mabrouk N, Scagliarini A, Reveneau S, Arnould L, Bettaieb A, Jeannin JF, Paul C.

Oncotarget. 2018 Jun 19;9(47):28364-28378. doi: 10.18632/oncotarget.25342. eCollection 2018 Jun 19.

9.

Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases.

Alsadoun N, MacGrogan G, Truntzer C, Lacroix-Triki M, Bedgedjian I, Koeb MH, El Alam E, Medioni D, Parent M, Wuithier P, Robert I, Boidot R, Arnould L.

Mod Pathol. 2018 Sep;31(9):1367-1380. doi: 10.1038/s41379-018-0047-1. Epub 2018 May 21.

PMID:
29785016
10.

Association between the retinal vascular network with Singapore "I" Vessel Assessment (SIVA) software, cardiovascular history and risk factors in the elderly: The Montrachet study, population-based study.

Arnould L, Binquet C, Guenancia C, Alassane S, Kawasaki R, Daien V, Tzourio C, Kawasaki Y, Bourredjem A, Bron A, Creuzot-Garcher C.

PLoS One. 2018 Apr 3;13(4):e0194694. doi: 10.1371/journal.pone.0194694. eCollection 2018.

11.

High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast.

Bataillon G, Fuhrmann L, Girard E, Menet E, Laé M, Capovilla M, Treilleux I, Arnould L, Penault-Llorca F, Rouzier R, Marchiò C, Bieche I, Vincent-Salomon A.

Histopathology. 2018 Aug;73(2):273-283. doi: 10.1111/his.13514. Epub 2018 May 7.

12.

Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.

Croce S, Ducoulombier A, Ribeiro A, Lesluyes T, Noel JC, Amant F, Guillou L, Stoeckle E, Devouassoux-Shisheboran M, Penel N, Floquet A, Arnould L, Guyon F, Mishellany F, Chakiba C, Cuppens T, Zikan M, Leroux A, Frouin E, Farre I, Genestie C, Valo I, MacGrogan G, Chibon F.

Mod Pathol. 2018 May;31(5):816-828. doi: 10.1038/modpathol.2017.185. Epub 2018 Jan 12.

PMID:
29327710
13.

Dry eye disease in the elderly in a French population-based study (the Montrachet study: Maculopathy, Optic Nerve, nuTRition, neurovAsCular and HEarT diseases): Prevalence and associated factors.

Ferrero A, Alassane S, Binquet C, Bretillon L, Acar N, Arnould L, Muselier-Mathieu A, Delcourt C, Bron AM, Creuzot-Garcher C.

Ocul Surf. 2018 Jan;16(1):112-119. doi: 10.1016/j.jtos.2017.09.008. Epub 2017 Sep 20.

PMID:
28939118
14.

Trends in operating room-based glaucoma procedures in France from 2005 to 2014: a nationwide study.

Bron AM, Mariet AS, Benzenine E, Arnould L, Daien V, Korobelnik JF, Quantin C, Creuzot-Garcher C.

Br J Ophthalmol. 2017 Nov;101(11):1500-1504. doi: 10.1136/bjophthalmol-2016-309946. Epub 2017 Mar 14.

PMID:
28292777
15.

Breast cancer subtype of French women is not influenced by socioeconomic status: A population-based-study.

Auguste A, Cortet M, Dabakuyo-Yonli TS, Launay L, Arnould L, Desmoulins I, Roignot P, Darut-Jouve A, Poillot ML, Bertaut A, Arveux P.

PLoS One. 2017 Feb 15;12(2):e0170069. doi: 10.1371/journal.pone.0170069. eCollection 2017.

16.

[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives].

Ladoire S, Derangère V, Arnould L, Thibaudin M, Coudert B, Lorgis V, Desmoulins I, Chaix M, Fumoleau P, Ghiringhelli F.

Ann Pathol. 2017 Feb;37(1):133-141. doi: 10.1016/j.annpat.2016.12.012. Epub 2017 Jan 31. Review. French.

PMID:
28159406
17.

Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.

Jankowski C, Guiu S, Cortet M, Charon-Barra C, Desmoulins I, Lorgis V, Arnould L, Fumoleau P, Coudert B, Rouzier R, Coutant C, Reyal F.

Breast Cancer Res Treat. 2017 Jan;161(1):73-81. doi: 10.1007/s10549-016-4040-4. Epub 2016 Nov 2.

PMID:
27807808
18.

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

Eliade M, Skrzypski J, Baurand A, Jacquot C, Bertolone G, Loustalot C, Coutant C, Guy F, Fumoleau P, Duffourd Y, Arnould L, Delignette A, Padéano MM, Lepage C, Raichon-Patru G, Boudrant A, Bône-Lépinoy MC, Villing AL, Charpin A, Peignaux K, Chevrier S, Vegran F, Ghiringhelli F, Boidot R, Sevenet N, Lizard S, Faivre L.

Oncotarget. 2017 Jan 10;8(2):1957-1971. doi: 10.18632/oncotarget.12699.

19.

Spatial Distribution of Macular Pigment in an Elderly French Population: The Montrachet Study.

Alassane S, Binquet C, Arnould L, Fleck O, Acar N, Delcourt C, Bretillon L, Bron AM, Creuzot-Garcher C.

Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4469-4475. doi: 10.1167/iovs.16-19958.

PMID:
27750290
20.

[Non-metastatic triple-negative breast cancer in 2016: Definitions and management].

Portha H, Jankowski C, Cortet M, Desmoulins I, Martin E, Lorgis V, Arnould L, Coutant C.

Gynecol Obstet Fertil. 2016 Sep;44(9):492-504. doi: 10.1016/j.gyobfe.2016.06.014. Epub 2016 Jul 19. Review. French.

PMID:
27451066
21.

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.

Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, Boyault S, Mulugeta E, Treilleux I, MacGrogan G, Arnould L, Kielbassa J, Le Texier V, Blanché H, Deleuze JF, Jacquemier J, Mathieu MC, Penault-Llorca F, Bibeau F, Mariani O, Mannina C, Pierga JY, Trédan O, Bachelot T, Bonnefoi H, Romieu G, Fumoleau P, Delaloge S, Rios M, Ferrero JM, Tarpin C, Bouteille C, Calvo F, Gut IG, Gut M, Martin S, Nik-Zainal S, Stratton MR, Pauporté I, Saintigny P, Birnbaum D, Viari A, Thomas G.

Nat Commun. 2016 Jul 13;7:12222. doi: 10.1038/ncomms12222.

22.

Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients.

Hennequin A, Derangère V, Boidot R, Apetoh L, Vincent J, Orry D, Fraisse J, Causeret S, Martin F, Arnould L, Beltjens F, Ghiringhelli F, Ladoire S.

Oncoimmunology. 2015 Jun 3;5(2):e1054598. eCollection 2016 Feb.

23.

Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.

Kaderbhai CG, Boidot R, Beltjens F, Chevrier S, Arnould L, Favier L, Lagrange A, Coudert B, Ghiringhelli F.

Oncotarget. 2016 Apr 26;7(17):24860-70. doi: 10.18632/oncotarget.8391.

24.

The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer.

Ladoire S, Enot D, Senovilla L, Ghiringhelli F, Poirier-Colame V, Chaba K, Semeraro M, Chaix M, Penault-Llorca F, Arnould L, Poillot ML, Arveux P, Delaloge S, Andre F, Zitvogel L, Kroemer G.

Autophagy. 2016 May 3;12(5):864-75. doi: 10.1080/15548627.2016.1154244. Epub 2016 Mar 16.

25.

LIN7A is a major determinant of cell-polarity defects in breast carcinomas.

Gruel N, Fuhrmann L, Lodillinsky C, Benhamo V, Mariani O, Cédenot A, Arnould L, Macgrogan G, Sastre-Garau X, Chavrier P, Delattre O, Vincent-Salomon A.

Breast Cancer Res. 2016 Feb 17;18(1):23. doi: 10.1186/s13058-016-0680-x.

26.

[An IgG4-related pancreatitis mimicking an adenocarcinoma: A case report].

Courcet E, Beltjens F, Charon-Barra C, Guy F, Orry D, Ghiringhelli F, Arnould L.

Ann Pathol. 2015 Dec;35(6):511-4. doi: 10.1016/j.annpat.2015.05.017. Epub 2015 Nov 17. Review. French.

PMID:
26596693
27.

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.

Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thürlimann B, Harvey V, Neven P, Arnould L, Maibach R, Price KN, Coates AS, Goldhirsch A, Gelber RD, Pagani O, Viale G, Rae JM, Regan MM; BIG 1-98 Collaborative Group.

Breast Cancer Res Treat. 2015 Dec;154(3):543-55. doi: 10.1007/s10549-015-3634-6. Epub 2015 Nov 21.

28.

Les biopsies des vésicules séminales restent indispensables à l'ère de l'IRM et du TEP à la choline pour la prise en charge des récidives après radiothérapie ou curiethérapie pour cancer de la prostate.

Barbier V, Hardy J, Kanoun S, Cochet A, Arnould L, Crehange G, Cormier L.

Prog Urol. 2015 Nov;25(13):733. doi: 10.1016/j.purol.2015.08.035. French. No abstract available.

PMID:
26544230
29.

Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer.

Ladoire S, Penault-Llorca F, Senovilla L, Dalban C, Enot D, Locher C, Prada N, Poirier-Colame V, Chaba K, Arnould L, Ghiringhelli F, Fumoleau P, Spielmann M, Delaloge S, Poillot ML, Arveux P, Goubar A, Andre F, Zitvogel L, Kroemer G.

Autophagy. 2015;11(10):1878-90. doi: 10.1080/15548627.2015.1082022.

30.

HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable.

Beltjens F, Bertaut A, Pigeonnat S, Loustalot C, Desmoulins I, Charon-Barra C, Coudert B, Fumoleau P, Arveux P, Arnould L.

Eur J Cancer Care (Engl). 2017 Mar;26(2). doi: 10.1111/ecc.12404. Epub 2015 Oct 27.

PMID:
26503126
31.

The Montrachet Study: study design, methodology and analysis of visual acuity and refractive errors in an elderly population.

Creuzot-Garcher C, Binquet C, Daniel S, Bretillon L, Acar N, de Lazzer A, Arnould L, Tzourio C, Bron AM, Delcourt C.

Acta Ophthalmol. 2016 Mar;94(2):e90-7. doi: 10.1111/aos.12842. Epub 2015 Oct 15.

32.

Liver X receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRβ subcellular localization.

Courtaut F, Derangère V, Chevriaux A, Ladoire S, Cotte AK, Arnould L, Boidot R, Rialland M, Ghiringhelli F, Rébé C.

Oncotarget. 2015 Sep 29;6(29):26651-62. doi: 10.18632/oncotarget.5791.

33.

Secretory Breast Carcinoma: A Histopathologic and Genomic Spectrum Characterized by a Joint Specific ETV6-NTRK3 Gene Fusion.

Del Castillo M, Chibon F, Arnould L, Croce S, Ribeiro A, Perot G, Hostein I, Geha S, Bozon C, Garnier A, Lae M, Vincent-Salomon A, MacGrogan G.

Am J Surg Pathol. 2015 Nov;39(11):1458-67. doi: 10.1097/PAS.0000000000000487.

PMID:
26291510
34.

Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.

Guiu S, Charon-Barra C, Vernerey D, Fumoleau P, Campone M, Spielmann M, Roché H, Mesleard C, Arnould L, Lemonnier J, Lacroix-Triki M.

Future Oncol. 2015;11(16):2283-97. doi: 10.2217/fon.15.102.

PMID:
26260807
35.

SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas.

Karanian-Philippe M, Velasco V, Longy M, Floquet A, Arnould L, Coindre JM, Le Naoures-Méar C, Averous G, Guyon F, MacGrogan G, Croce S.

Am J Surg Pathol. 2015 Sep;39(9):1197-205. doi: 10.1097/PAS.0000000000000475.

PMID:
26135561
36.

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.

Ng CK, Martelotto LG, Gauthier A, Wen HC, Piscuoglio S, Lim RS, Cowell CF, Wilkerson PM, Wai P, Rodrigues DN, Arnould L, Geyer FC, Bromberg SE, Lacroix-Triki M, Penault-Llorca F, Giard S, Sastre-Garau X, Natrajan R, Norton L, Cottu PH, Weigelt B, Vincent-Salomon A, Reis-Filho JS.

Genome Biol. 2015 May 22;16:107. doi: 10.1186/s13059-015-0657-6.

37.

Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.

Croce S, Ribeiro A, Brulard C, Noel JC, Amant F, Stoeckle E, Devouassoux-Shisheborah M, Floquet A, Arnould L, Guyon F, Mishellany F, Garbay D, Cuppens T, Zikan M, Leroux A, Frouin E, Duvillard P, Terrier P, Farre I, Valo I, MacGrogan GM, Chibon F.

Mod Pathol. 2015 Jul;28(7):1001-10. doi: 10.1038/modpathol.2015.3. Epub 2015 May 1.

38.

Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHORA.

Spano JP, Beuzeboc P, Coeffic D, Arnould L, Lortholary A, Andre F, Ferrero JM.

Breast. 2015 Aug;24(4):376-83. doi: 10.1016/j.breast.2015.02.035. Epub 2015 Apr 23.

PMID:
25913287
39.

Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy.

Schmitt E, Végran F, Chevrier S, Burillier L, Cadouot M, Lizard-Nacol S, Coudert B, Fumoleau P, Arnould L, Boidot R.

BMC Cancer. 2015 Mar 24;15:169. doi: 10.1186/s12885-015-1198-9.

40.

Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status.

Bertaut A, Mounier M, Desmoulins I, Guiu S, Beltjens F, Darut-Jouve A, Ponnelle T, Arnould L, Arveux P.

Eur J Cancer Care (Engl). 2015 Nov;24(6):920-8. doi: 10.1111/ecc.12306. Epub 2015 Mar 10.

PMID:
25757548
41.

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.

Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupré PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A.

Lancet Oncol. 2014 Dec;15(13):1493-502. doi: 10.1016/S1470-2045(14)70475-9. Epub 2014 Oct 30.

PMID:
25456368
42.

[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France].

MacGrogan G, Mathieu MC, Poulet B, Penault-Llorca F, Vincent-Salomon A, Roger P, Treilleux I, Valent A, Antoine M, Becette V, Bor C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Devouassoux M, Fiche M, Fondrevelle ME, Fridman V, Garbar C, Genin P, Ghnassia JP, Haudebourg J, Laberge-Le Couteulx S, Loussouarn D, Maran-Gonzalez A, Marcy M, Michenet P, Sagan C, Trassard M, Verriele V, Arnould L, Lacroix-Triki M; GEFPICS.

Ann Pathol. 2014 Oct;34(5):366-72. doi: 10.1016/j.annpat.2014.08.017. Epub 2014 Sep 26. French.

PMID:
25439989
43.

[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].

Penault-Llorca F, Vincent-Salomon A, MacGrogan G, Roger P, Treilleux I, Valent A, Mathieu MC, Antoine M, Becette V, Bor C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Devouassoux M, Fiche M, Fondrevelle ME, Fridman V, Garbar C, Genin P, Ghnassia JP, Haudebourg J, Laberge-Le Couteulx S, Loussouarn D, Maran-Gonzalez A, Marcy M, Michenet P, Poulet B, Sagan C, Trassard M, Verriele V, Arnould L, Lacroix-Triki M; GEFPICS.

Ann Pathol. 2014 Oct;34(5):352-65. doi: 10.1016/j.annpat.2014.08.018. Epub 2014 Sep 26. French.

PMID:
25439988
44.

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tüting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Préville X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André F, Kroemer G, Zitvogel L.

Nat Med. 2014 Nov;20(11):1301-9. doi: 10.1038/nm.3708. Epub 2014 Oct 26.

PMID:
25344738
45.

Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations.

Chevrier S, Arnould L, Ghiringhelli F, Coudert B, Fumoleau P, Boidot R.

Int J Oncol. 2014 Sep;45(3):1167-74. doi: 10.3892/ijo.2014.2528. Epub 2014 Jun 27.

PMID:
24990411
46.

Polarity gene alterations in pure invasive micropapillary carcinomas of the breast.

Gruel N, Benhamo V, Bhalshankar J, Popova T, Fréneaux P, Arnould L, Mariani O, Stern MH, Raynal V, Sastre-Garau X, Rouzier R, Delattre O, Vincent-Salomon A.

Breast Cancer Res. 2014 May 8;16(3):R46. doi: 10.1186/bcr3653.

47.

Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.

Jary M, Ghiringhelli F, Jacquin M, Fein F, Nguyen T, Cleau D, Nerich V, El Gani M, Mathieu P, Valmary-Degano S, Arnould L, Lassabe C, Lamfichekh N, Fratté S, Paget-Bailly S, Bonnetain F, Borg C, Kim S.

Cancer Chemother Pharmacol. 2014 Jul;74(1):141-50. doi: 10.1007/s00280-014-2482-0. Epub 2014 May 14.

PMID:
24824852
48.

HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.

Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B, Desmoulins I, Toubeau M, Dygai-Cochet I, Guiu S, Coutant C, Fumoleau P, Brunotte F.

Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1525-33. doi: 10.1007/s00259-014-2739-1. Epub 2014 Mar 20.

PMID:
24647576
49.

Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene.

Degrolard-Courcet E, Sokolowska J, Padeano MM, Guiu S, Bronner M, Chery C, Coron F, Lepage C, Chapusot C, Loustalot C, Jouve JL, Hatem C, Ferrant E, Martin L, Coutant C, Baurand A, Couillault G, Delignette A, El Chehadeh S, Lizard S, Arnould L, Fumoleau P, Callier P, Mugneret F, Philippe C, Frebourg T, Jonveaux P, Faivre L.

Eur J Hum Genet. 2014 Aug;22(8):979-87. doi: 10.1038/ejhg.2013.278. Epub 2013 Dec 4. Review.

50.

Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study.

Franchet C, Filleron T, Cayre A, Mounié E, Penault-Llorca F, Jacquemier J, Macgrogan G, Arnould L, Lacroix-Triki M.

Histopathology. 2014 Jan;64(2):274-83. doi: 10.1111/his.12247. Epub 2013 Oct 1.

PMID:
24117939

Supplemental Content

Loading ...
Support Center